Skip to main content
Erschienen in: Wiener klinische Wochenschrift 9-10/2012

01.05.2012 | konsensus bericht

Leitlinie zur Prävention und Früherkennung von Brust- und Eierstockkrebs bei Hochrisikopatientinnen, insbesondere bei Frauen aus HBOC (Hereditary Breast and Ovarian Cancer) Familien

verfasst von: Christian F. Singer, M.D., Muy-Kheng Tea, MD, Gunda Pristauz, MD, Michael Hubalek, MD, Christine Rappaport, MS, Christopher Riedl, MD, Thomas Helbich, MD, MBA

Erschienen in: Wiener klinische Wochenschrift | Ausgabe 9-10/2012

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die vorliegende österreichische Leitlinie zur Prävention und Früherkennung von Brust- und Eierstockkrebs bei Hochrisikopatientinnen – insbesondere bei Frauen aus HBOC-Familien – wurde unter der besonderen Berücksichtigung des aktuellen EUSOMA (European Society of Breast Cancer Specialists) Positionspapiers von oben angeführten Experten gemeinsam erstellt. Die Leitlinie soll die Betreuung von Frauen mit einem erhöhtem Lebenszeitrisiko für Brust- und/oder Eierstockkrebs standardisieren und vereinfachen.
Literatur
1.
Zurück zum Zitat Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010 May;46(8):1296–316.PubMedCrossRef Sardanelli F, Boetes C, Borisch B, Decker T, Federico M, Gilbert FJ, et al. Magnetic resonance imaging of the breast: recommendations from the EUSOMA working group. Eur J Cancer. 2010 May;46(8):1296–316.PubMedCrossRef
2.
Zurück zum Zitat Jatoi I, Anderson WF. Management of women who have a genetic predisposition for breast cancer. Surg Clin North Am. 2008 Aug;88(4):845–61.PubMedCrossRef Jatoi I, Anderson WF. Management of women who have a genetic predisposition for breast cancer. Surg Clin North Am. 2008 Aug;88(4):845–61.PubMedCrossRef
3.
Zurück zum Zitat Sardanelli F, Podo F. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007 Oct 18;357(16):1663.PubMedCrossRef Sardanelli F, Podo F. Management of an inherited predisposition to breast cancer. N Engl J Med. 2007 Oct 18;357(16):1663.PubMedCrossRef
4.
Zurück zum Zitat Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. 2007 Apr;17(4):873–87.PubMedCrossRef Sardanelli F, Podo F. Breast MR imaging in women at high-risk of breast cancer. Is something changing in early breast cancer detection? Eur Radiol. 2007 Apr;17(4):873–87.PubMedCrossRef
5.
Zurück zum Zitat Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004 Sep 15;292(11):1317–25.PubMedCrossRef Warner E, Plewes DB, Hill KA, Causer PA, Zubovits JT, Jong RA, et al. Surveillance of BRCA1 and BRCA2 mutation carriers with magnetic resonance imaging, ultrasound, mammography, and clinical breast examination. JAMA. 2004 Sep 15;292(11):1317–25.PubMedCrossRef
6.
Zurück zum Zitat Riedl CC, Ponhold L, Flöry D, Weber M, Kroiss R, Wagner T, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res. 2007 Oct 15;13(20):6144–52.PubMedCrossRef Riedl CC, Ponhold L, Flöry D, Weber M, Kroiss R, Wagner T, et al. Magnetic resonance imaging of the breast improves detection of invasive cancer, preinvasive cancer, and premalignant lesions during surveillance of women at high risk for breast cancer. Clin Cancer Res. 2007 Oct 15;13(20):6144–52.PubMedCrossRef
7.
Zurück zum Zitat Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat. 2006 Nov;100(1):109–19.PubMedCrossRef Kriege M, Brekelmans CT, Obdeijn IM, Boetes C, Zonderland HM, Muller SH, et al. Factors affecting sensitivity and specificity of screening mammography and MRI in women with an inherited risk for breast cancer. Breast Cancer Res Treat. 2006 Nov;100(1):109–19.PubMedCrossRef
9.
Zurück zum Zitat Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967–75.PubMedCrossRef Domchek SM, Friebel TM, Singer CF, Evans DG, Lynch HT, Isaacs C, et al. Association of risk-reducing surgery in BRCA1 or BRCA2 mutation carriers with cancer risk and mortality. JAMA. 2010 Sep 1;304(9):967–75.PubMedCrossRef
10.
Zurück zum Zitat Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331–7.PubMedCrossRef Kauff ND, Domchek SM, Friebel TM, Robson ME, Lee J, Garber JE, et al. Risk-reducing salpingo-oophorectomy for the prevention of BRCA1- and BRCA2-associated breast and gynecologic cancer: a multicenter, prospective study. J Clin Oncol. 2008 Mar 10;26(8):1331–7.PubMedCrossRef
11.
Zurück zum Zitat Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15;22(12):2328–35.PubMedCrossRef Metcalfe K, Lynch HT, Ghadirian P, Tung N, Olivotto I, Warner E, et al. Contralateral breast cancer in BRCA1 and BRCA2 mutation carriers. J Clin Oncol. 2004 Jun 15;22(12):2328–35.PubMedCrossRef
12.
Zurück zum Zitat Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748. Lostumbo L, Carbine NE, Wallace J. Prophylactic mastectomy for the prevention of breast cancer. Cochrane Database Syst Rev. 2010 Nov 10;(11):CD002748.
13.
Zurück zum Zitat Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15;22(6):1055–62.PubMedCrossRef Rebbeck TR, Friebel T, Lynch HT, Neuhausen SL, van’t Veer L, Garber JE, et al. Bilateral prophylactic mastectomy reduces breast cancer risk in BRCA1 and BRCA2 mutation carriers: the PROSE Study Group. J Clin Oncol. 2004 Mar 15;22(6):1055–62.PubMedCrossRef
14.
Zurück zum Zitat Metcalfe KA. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Womens Health (Lond Engl). 2009 Jan;5(1):63–8.CrossRef Metcalfe KA. Oophorectomy for breast cancer prevention in women with BRCA1 or BRCA2 mutations. Womens Health (Lond Engl). 2009 Jan;5(1):63–8.CrossRef
15.
Zurück zum Zitat Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms; W. Zuckschwerdt Verlag GmbH,Aktualisierung 2008; ISBN 978-3-88603-934-0. Interdisziplinäre S3-Leitlinie für die Diagnostik, Therapie und Nachsorge des Mammakarzinoms; W. Zuckschwerdt Verlag GmbH,Aktualisierung 2008; ISBN 978-3-88603-934-0.
16.
Zurück zum Zitat Balmaña J, Díez O, Castiglione M, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO clinical recommendations. Ann Oncol. 2009 May;20(Suppl 4):19–20. Balmaña J, Díez O, Castiglione M, ESMO Guidelines Working Group. BRCA in breast cancer: ESMO clinical recommendations. Ann Oncol. 2009 May;20(Suppl 4):19–20.
17.
Zurück zum Zitat ACOG and SGO Practice Bulletin. Hereditary breast an ovarian syndrome. Am J Obstet Gynecol. 2009;113:957–65. ACOG and SGO Practice Bulletin. Hereditary breast an ovarian syndrome. Am J Obstet Gynecol. 2009;113:957–65.
18.
Zurück zum Zitat Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, et al. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. National Hereditary Cancer Task Force. J Obstet Gynaecol Can. 2007 Jan;29(1):45–60.PubMed Horsman D, Wilson BJ, Avard D, Meschino WS, Kim Sing C, Plante M, et al. Clinical management recommendations for surveillance and risk-reduction strategies for hereditary breast and ovarian cancer among individuals carrying a deleterious BRCA1 or BRCA2 mutation. National Hereditary Cancer Task Force. J Obstet Gynaecol Can. 2007 Jan;29(1):45–60.PubMed
19.
Zurück zum Zitat Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75–89.PubMedCrossRef Saslow D, Boetes C, Burke W, Harms S, Leach MO, Lehman CD, et al. American cancer society guidelines for breast screening with MRI as an adjunct to mammography. CA Cancer J Clin. 2007 Mar-Apr;57(2):75–89.PubMedCrossRef
20.
Zurück zum Zitat http://www.breastsurgeons.org/statements/brca.php. http://www.breastsurgeons.org/statements/brca.php.
Metadaten
Titel
Leitlinie zur Prävention und Früherkennung von Brust- und Eierstockkrebs bei Hochrisikopatientinnen, insbesondere bei Frauen aus HBOC (Hereditary Breast and Ovarian Cancer) Familien
verfasst von
Christian F. Singer, M.D.
Muy-Kheng Tea, MD
Gunda Pristauz, MD
Michael Hubalek, MD
Christine Rappaport, MS
Christopher Riedl, MD
Thomas Helbich, MD, MBA
Publikationsdatum
01.05.2012
Verlag
Springer Vienna
Erschienen in
Wiener klinische Wochenschrift / Ausgabe 9-10/2012
Print ISSN: 0043-5325
Elektronische ISSN: 1613-7671
DOI
https://doi.org/10.1007/s00508-012-0173-6

Weitere Artikel der Ausgabe 9-10/2012

Wiener klinische Wochenschrift 9-10/2012 Zur Ausgabe